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Abstract 
The broad substrate capacity of the intestinal oligopeptide transporter, PepT1, has made it a key 
target of research into drug delivery. Whilst the substrate capacity of this transporter is broad, 
studies have largely been limited to small peptides and peptide-like drugs. Here, we demonstrate for 
the first time that a diverse range of drugs can be targeted towards transport by PepT1 using a 
hydrolysis resistant carrier. Eleven prodrugs were synthesised by conjugating modified dipeptides 
containing a thioamide bond to the approved drugs ibuprofen, gabapentin, propofol, aspirin, 
acyclovir, nabumetone, atenolol, zanamivir, baclofen and mycophenolate. Except for the aspirin and 
acyclovir prodrugs, which were unstable in the assay conditions and were not further studied, the 
prodrugs were tested for affinity and transport by PepT1 expressed in Xenopus laevis oocytes: 
binding affinities ranged from approximately 0.1 to 2 mM. Compounds which showing robust 
transport in an oocyte trans stimulation assay were then tested for transcellular transport in Caco-2 
cell monolayers: all five tested prodrugs showed significant PepT1-mediated transcellular uptake. 
Finally, the ibuprofen and propofol prodrugs were tested for absorption in rats:  following oral 
dosing the intact prodrugs and free ibuprofen were measured in the plasma. This provides proof-of-
concept for the idea of targeting poorly bioavailable drugs towards PepT1 transport as a general 
means of improving oral permeability.  
Keywords 
Prodrug; membrane transporter; intestine; PepT1; drug delivery 
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Introduction 
The oral bioavailability of a compound is a crucial factor in its success or failure as a therapeutic 
agent, particularly given the convenience of this route of administration. There are two main 
mechanisms of absorption from the GI tract: passive diffusion [1] and carrier mediated transport [2].  
The oral bioavailability of poorly absorbed drugs can be improved either by modifying their 
physicochemical properties to aid passive diffusion and/or by targeting of the compounds towards 
carrier mediated transport [3-5].  
PepT1 is a proton coupled oligopeptide transporter expressed principally in the small intestine and 
the proximal tubule of the kidney [6]. It has a broad substrate specificity including most di- and 
tripeptides, β-lactam antibiotics and ACE inhibitors [7]. 
There are many examples of targeting PepT1 to improve the oral bioavailability of pharmacologically 
active compounds, usually by modifying them so that they resemble the natural di- or tripeptide 
substrates [8-13].  We have patented [14] a set of thiodipeptide substrates (such as A and B) that we 
hope can act as “carriers” for drug transport by PepT1 generally, and have previously published our 
work on model systems demonstrating that a variety of linkers can be employed [15, 16]. The basic 
premise is illustrated in Figure 1 in which drugs are conjugated directly or by a linker to our 
thiodipeptides, converting them into prodrugs that are PepT1 substrates. 
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Figure 1. PepT1 as a drug delivery target. Drugs are attached to the side-chains of the seryl (A) or aspartyl (B) thiodipeptide 
carriers, directly or via linkers, forming prodrug substrates of PepT1.  
In this paper, we apply the results of our previously reported characterisation of the structure-
transport relationships for PepT1 [15] to drug delivery challenges and report proof-of-concept 
studies that validate the use of our thiodipeptide carriers as a general approach for targeting a 
variety of drugs towards PepT1 mediated transport. We focused on two major areas that we felt 
could benefit from our thiodipeptide drug delivery technology:  
i) Drugs with GI side effects. A common class of such drugs are the NSAIDs, as exemplified by aspirin 
and ibuprofen [17]. Whilst these drugs have high oral bioavailability, they also can cause severe 
gastric side effects. If a prodrug strategy could be developed so that bioavailability was retained, but 
active drug was not released close to the GI tract, such side effects might be significantly reduced. 
Prodrugs 1, 4 and 6-7 of ibuprofen, aspirin and nabumetone respectively (Figure 2) were synthesized 
to explore this area. 
ii) Drugs with poor oral bioavailability. This is a major challenge in drug development. A search of 
ChEMBL [18] identified several marketed drugs with low, highly variable or no oral bioavailability 
[17]: gabapentin (an anticonvulsant and analgesic); baclofen (a GABA receptor agonist); propofol 
(chemotherapeutic nausea and intractable migraine); zanamivir (treatment and prophylaxis of 
influenza) and mycophenolic acid (an immunosuppressant). Prodrugs 2, 3, 5, and 8-11 (Figure 2) 
were synthesized to prove our concept in this important area. 
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Figure 2. Rationally designed prodrugs to target PepT1 (parent drug in brackets). 
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Chemistry 
The synthesis of the protected serine and aspartate carrier thiodipeptides (12 and 13), nabumetone 
prodrugs 6-7 and ibuprofen prodrug 1 have been reported previously [15, 16]. Our chosen drugs 
could readily be attached to the appropriate carrier using standard coupling reagents, except for the 
aspirin prodrug 4 (Table 1). This was synthesized by first using concentrated Mitsunobu conditions 
[19] with sonication to esterify the salicylic acid with triethylene glycol to give 22, then coupling this 
glycol ester to the aspartate carrier using standard coupling conditions (Scheme 1) to give 23. This 
indirect route was chosen because we were unable to accomplish direct esterification of aspirin with 
the serine carrier using a variety of coupling conditions. Deprotection was usually achieved in >85% 
yield using either a 33% solution of TFA in DCM or neat formic acid, except for 5, for which 
decomposition was avoided by using phenol as solvent [20]. Since the NMR [15] of carriers 12 and 13 
show no signs of epimerisation, and rotamers observed in the NMR of some final compounds have 
spectral characteristics consistent with cis/trans rotamers around the thioamide bond as we have 
previously reported [21]. 
 
 
 
 
  
Drug Coupling Agent Compound (Yield) 
Gabapentin (Boc protected) HBTU 14 (22%) 
Propofol DCC 15 (38%) 
Acyclovir DCC 16 (96%) 
Atenolol (Boc protected) CDI 17 (36%) 
Zanamivir HATU 18 (11%) 
Baclofen (Boc protected) DCC 19 (65%) 
Mycophenolic acid HATU 20 (20%) 
Table 1. Synthesis of protected pro-drugs (non-optimized yields) 
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Scheme 1. Synthesis of protected aspirin pro-drug. (i) PPh3, triethylene glycol, DIAD, THF, rt, sonication, 15 min. (ii) 13 [15], 
HBTU, DIPEA, DMF, rt, 4 days. 
 
Results and Discussion 
The results of binding studies, trans-stimulation and Caco-2 monolayer assays are summarised in 
Table 2. The binding affinities of all prodrugs for PepT1 were determined by measuring the 
concentration at which they inhibit uptake of radiolabelled D-Phe-L-Gln in Xenopus laevis oocytes 
expressing rabbit PepT1. Inhibition constants were calculated from standard Michaelis-Menten 
kinetics [22, 23]. PepT1 is a low affinity, high capacity transporter and compounds with an affinity < 1 
mM are generally classed as high affinity binders of the transporter. Figure 3 shows the data for 
prodrugs 1 and 3, which are representative of those determined for all the prodrugs. Prodrugs 4 and 
5 had limited stability in the pH 5.5 assay buffer (multiple HPLC peaks), and so no reliable affinity or 
transport data could be generated. 
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Compound  
(parent drug) 
Ki (mM) Trans-stimulated 
efflux? 
Overall Papp 
(x 10
-6
 cm s
-1
) 
(Normalised
a
) 
PepT1 Papp 
(x 10
-6
 cm s
-1
) 
(Normalised
a
)Ft 
FSA (control) 0.32 ± 0.08 No 3.0 ± 0.5 (1.00) 1.9 ± 0.5 (1.00) 
1 (ibuprofen) 0.26 ± 0.03 Yes 3.7 ± 0.2 (1.29) 2.1 ± 0.3 (1.07) 
2 (gabapentin) 1.01 ± 0.33 Yes 0.6 ± 0.1 (0.46) 0.4 ± 0.1 (0.69) 
3 (propofol) 0.92 ± 0.19 Yes 0.5 ± 0.1 (0.41) 0.5 ± 0.1 (0.89) 
4 (aspirin) ndb    
5 (acyclovir) ndb    
6
c (nabumetone) 0.08 ± 0.02 Yes 9.7 ± 0.1 (1.94) 4.4 ± 0.2 (1.30) 
7
c (nabumetone) 0.46 ± 0.09 Yes 7.8 ± 0.2 (3.78) 6.3 ± 0.1 (6.52) 
8 (atenolol) 0.44 ± 0.15 No nd nd 
9 (zanamivir) 0.13 ± 0.02 No nd nd 
10 (baclofen) 1.87 ± 0.26 No nd nd 
11 (mycophenolate) 0.21 ± 0.08 Weak nd nd 
Table 2. Summary of in vitro affinity and transport studies on rationally design prodrugs in oocytes and Caco-2 monolayers. 
a The PheΨ[CS-NH]-Ala (FSA) value is the mean ± RSD of six separate experiments with at least three monolayers. 
All other results are the mean ± RSD of one experiment with at least three monolayers. The normalized figure is to 
the FSA value recorded in that experiment. b Prodrug was unstable to assay buffer (pH 5.5). c Previously reported 
data [16]. 
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Figure 3. The Ki of prodrugs 1 and 3 for rabbit PepT1 expressed in Xenopus laevis oocytes. 
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As binding studies only show affinity for PepT1 and do not provide information as to whether the 
compound is a substrate or an inhibitor, further transport experiments were undertaken. Trans-
stimulation assays were performed using radiolabelled [3H]-D-Phe-L-Gln efflux from rabbit PepT1 
expressing oocytes in the presence of 10 mM pro-drug. As controls, 10 mM Gly-L-Gln (a standard 
PepT1 substrate) or buffer lacking a substrate (negative control) were used. Figure 4 shows the 
efflux data for the compounds summarised in Table 2. 
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Figure 4. Effect of incubation of 10 mM prodrugs on the trans-stimulation efflux of radiolabelled [3H]-D-Phe-L-Gln, 
compared to the known PepT1 substrate GlyGln 
Prodrugs 1-3, 6-7 and 11 induced statistically significant trans-stimulation efflux in oocytes, thereby 
demonstrating PepT1 mediated transport [22, 23]. Most of these induced similar or greater efflux 
than GlyGln, however prodrug 11 only weakly triggered efflux in comparison to GlyGln. 
Prodrugs that generated robust trans-stimulated efflux in oocytes were further in a Caco-2 
monolayer assay to investigate further the extent and rate of trans-epithelial transport. Caco-2 cells 
were chosen as they are widely accepted as a good overall model for the small intestinal epithelium 
[24], although it has been suggested that Caco-2 cells may underestimate the in vivo trans-epithelial 
rate of transport [25]. Apical to basolateral transport of 2 mM pro-drug, applied to the apical side, 
was monitored by high performance liquid chromatography (HPLC) after one hour. The presence or 
absence of excess Gly-Gln allowed us to determine both the overall and PepT1 specific permeability 
(Table 2). The remaining pro-drugs were significantly transported in both oocyte and Caco-2 
monolayer assays. The PepT1 mediated Papp values are of similar magnitude to known PepT1 
(pro)drug substrates [10, 16]. 
Based on these encouraging in vitro results, we elected to study 1 and 3 in vivo (Table 3), as simple 
examples of the two areas of interest to us. Administration of both 1 and 3 to rats resulted in intact 
prodrug being observed in the blood, with CMax of 0.2 and 16.7 µg/mL respectively observed. Release 
of ibuprofen was also observed upon administration of 1, with a relative bioavailability of 2% [26]. 
The shift in the TMax observed for ibuprofen following administration of 1 when compared to free 
ibuprofen (from 1 hour for free ibuprofen to 3.5 hours for 1) is indicative of a change in absorption 
mechanism. The low bioavailability of ibuprofen can be explained by the relative stability of the 
prodrug 1 to metabolism, as estimated by its in vitro half-life upon incubation with rat liver 
homogenate of over 17 hours. 
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Table 3. Preliminary in vivo results. Values are mean ± standard deviation for n = 3 male Sprague-Dawley rats. IV = intra 
venous dosing.   a As free base.  b As compared to L-Trp-L-Ala, which had a t1/2 of 0.15 hours under the same experimental 
conditions. 
Regrettably, we were unable to detect free propofol released following administration of prodrug 3 
because HPLC conditions to quantify free propofol could not be found. However, the relatively high 
CMax for the intact prodrug 3 is encouraging and despite the relative metabolic stability of 3 (7-hour 
half-life in rat liver homogenate) it is likely some free propofol would be available systemically. This 
is notable given the fact that propofol itself had no oral bioavailability in either rats or humans [27]. 
The low bioavailability of ibuprofen following administration of prodrug 1, combined with fact that 
both prodrug 1 and 3 were relatively resistant to liver metabolism indicates that further work is 
required to design effective prodrugs suitable for therapeutic application. Nevertheless, we believe 1 
and 3 serve as promising preliminary proof-of-concept to the idea that targeting PepT1 using our 
thiodipeptides can be used as a general strategy to overcoming oral bioavailability issues in drug 
discovery and development. 
Conclusions 
PepT1 is described in the literature as having a broad substrate capacity but, in reality, it has been 
limited to date to small peptides and peptide-like drugs. To better harness the capacity of this 
transporter as a drug delivery target, a rational and general targeting approach is required. We 
report here our data supporting a thiodipeptide prodrug as such a general targeting approach in 
vitro and in vivo. 
We were excited to find that nine out of eleven of our rationally designed PepT1 targeting prodrugs 
displayed high affinity binding towards PepT1, and six of them triggered trans-stimulation. 
Additionally, prodrugs 1-3, as well as 6-7 (as previously reported) [16], were all significantly 
transported in Caco-2 monolayers, with prodrugs 1 and 3 showing evidence of intact absorption in 
vivo. This provides proof-of-concept that diverse drug types can be delivered via a PepT1 mediated 
pathway using thiodipeptide carriers, with implications for future drug design strategies. Preliminary 
in vivo data also supports the use of thiodipeptide prodrugs to confer oral bioavailability. 
The drugs exemplified represent examples of several classes of drugs for which oral delivery could 
be therapeutically interesting. These include thiodipeptide prodrugs of NSAIDs (e.g. 1, 4, 6-7), which 
have high oral activity but also suffer from significant GI side effects. Examples of drugs for which 
oral activity is absent (e.g. 3), low (e.g. 9), or highly variable (2, 10) have also been successfully 
modified using our thiodipeptide approach, to target the PepT1 transporter.  
There is much future work to conduct before we can confidently say that rationally targeting PepT1 
is a general strategy for oral drug delivery. In particular, the complete in vivo DMPK profile of our 
prodrugs needs to be established and future prodrugs need to be optimised for rapid liver and/or 
Compound 
Dose
a
 
(mg kg
-1
)
 
Assayed 
compound 
CMax 
(μg mL
-1
) 
AUC 
(μg h mL
-1
) 
tmax 
(h) 
Rat liver 
homgenate
b
 
t1/2 (h) 
Relative F 
(%) 
Ibuprofen 6 Ibuprofen 5.7 ± 0.6 14.0 ± 1.8 0.7 ± 0.3  100 [26] 
1 10 
Intact 1 0.2 ± 0.04 0.5 ± 0.1 1.0 ± 0.0 17.9 -  
Ibuprofen 0.2 ± 0.02 0.7 ± 0.1 3.2 ± 0.2  2.8 ± 0.3 
3 7.6 Intact 3 16.3 ± 1.8 3.2 ± 1.4 5.2 ± 0.8 7.3 - 
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plasma esterase metabolism and release of free drug, or indeed potentially slower, sustained release 
if desired. Optimisation of the stability of the linker is also required, as evidenced by the instability of 
prodrugs 4 and 5. However, our previously reported work suggests that the transporter can 
accommodate a wide variety of linkers [15, 16], allowing scope to tailor the DMPK properties of a 
specific prodrug. 
The oral delivery of drugs is a major challenge in pre-clinical development and leads to significant 
shelving of promising lead candidates in drug discovery. Our prodrug approach may allow many such 
biologically active compounds to be re-evaluated by administration as PepT1 targeting thiodipeptide 
prodrugs. Our in vitro and preliminary in vivo data is highly encouraging and warrants further work. 
In particular, our recent report that large peptide drugs such as cyclosporine A [28] can be rationally 
targeted towards PepT1 using the same approach offers the tantalising possibility of PepT1 targeting 
as a solution to the delivery of both small and peptidic molecules.  
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Experimental Section 
In Vitro Biological Studies 
The Ki, trans-stimulation efflux and Caco-2 assays were performed as described previously [15, 16]. 
Fresh rat liver homogenate was prepared by isolating liver from euthanized male rats, according to 
approved Home Office procedures. The liver was chopped with scissors and rinsed with medium 
(0.25 M sucrose, 25 mM KCl, 5 mM MgCl2 and 50 mM Tris/HCl, pH7.5) to remove trapped blood. The 
liver was then homogenized in fresh medium with a loose-fitting dounce-type homogenizer and kept 
on ice. Liver homogenate was incubated with either 0. 5 mM compound 1 or 3, or L-Trp-L-Ala as a 
positive control, at 37°C. 250 µl aliquots of the homogenate were taken at 0, 0.25, 0.5, 1, 2, 6 and 24 
hours. The samples were precipitated by addition an equal volume of 3% perchloric acid and 
centrifugation at 17000 g for 5 minutes. The perchloric acid was neutralized with 250 µl of 1 M KOH, 
and the sample subjected to a freeze / thaw cycle to precipitate the KClO4 salt before again being 
centrifuged. The supernatant was then analysed by HPLC as for the Caco-2 permeability studies [15, 
16], and the half-life of the compounds calculated according to the method of Vig et al [29]. 
In vivo studies 
In vivo testing was carried out by Cyprotex Discovery Ltd., 15 Beech Lane, Macclesfield, Cheshire, 
SK10 2DR, United Kingdom or Saretius Ltd, Science & Technology Centre, Earley Gate, University of 
Reading, Reading, Berkshire RG6 6BZ, United Kingdom. 
Each test compound was administered orally as solutions in distilled water (ibuprofen, 1) or 
polypropylene glycol (3) to three adult male Sprague-Dawley weighing 250-300 g, which were 
housed singly following jugular vein cannulation prior to administration of compound. Animals were 
given free access to food and water throughout the study and maintained under a 12-hour light/dark 
cycle with temperature and humidity controlled according to Home Office regulations. All 
compounds were well-tolerated and no-adverse events were reported. 
Blood samples (230 µL) were taken from the carotid artery at the following time points and placed in 
heparinized tubes: predose, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose. After the final time point the 
animals were sacrificed by an overdose of anaesthetic. 
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Blood samples were centrifuged to obtain the plasma, which was transferred to a separate labelled 
container. Aliquots from the individual time points for the three animals were analyzed singly. 80 µL 
of plasma was diluted with 20 µL of 1:1 ACN:water, then 800 µL chilled ACN was added, samples 
briefly vortex mixed and the centrifuged at 13000 rpm for 5 minutes at 4 °C. 500 µL of the resultant 
supernatant was further diluted with 500 µL water. 
20 µL sample was analyzed by LC-MS/MS using a C18 5 µm Gemini UHPLC column running a gradient 
of 90% 0.04% acetic acid in water to 90% ACN over 3 minutes at a flow rate of 0.5 mL/min. MS data 
was acquired under multiple reaction monitoring conditions using a turbo spray ion source.  The 
concentration in the plasma was determined by comparison to standard curves of the administered 
compound prepared in blank plasma matrices and treated in an identical manner to the samples. 
Synthetic Chemistry 
Anhydrous solvents and reagents were obtained as follows: DMF was dried three times over 
molecular sieves (3 Å). THF was dried by distillation from sodium benzophenone ketyl, DCM and 
toluene by distillation from calcium hydride. All reactions were conducted at room temperature in 
dry glassware under a nitrogen atmosphere, unless otherwise stated. All chemicals were used 
directly from suppliers’ (Sigma-Aldrich) vessel without further purification, unless otherwise stated. 
Protected amino acids and HBTU were supplied by Novabiochem. 1H NMR spectra were recorded at 
300, 400 or 500 MHz and 13C NMR spectra at 75, 100 or 125 MHz on a Bruker AC300, AC400, Avance 
II or Varian Unity INOVA 300 spectrometers. Chemical shifts are denoted in ppm (δ) relative to the 
internal solvent standard. The splitting patterns for NMR spectra are designated as follows: s 
(singlet), br (broad), d (doublet), t (triplet), p (pentet), m (multiplet), or combinations thereof. 
Coupling constants (J) are designated in Hz and reported to 1 decimal place. Assignments were made 
with the aid of DEPT135, COSY and HMQC experiments. ES-MS (and HRMS) spectra were recorded 
on a Micromass LCT orthogonal acceleration time-of-flight mass spectrometer (positive ion mode) 
with flow injection via a Waters 2790 separation module autosampler. IR spectra were obtained 
using a Nicolet-Nexus 670/680 FT-IR or ATI Mattson Genesis Series FT-IR spectrometer and are 
quoted in cm-1. Optical rotations were measured at 589 nm in a 1 dm cell using an Optical Activity 
AA1000 polarimeter and are quoted in 10-2 deg cm2 g-1. Melting point determinations were made 
using a Stuart Scientific SMP1 apparatus and are uncorrected.  Analytical TLC was performed on 
Merck silica gel 60 F254 aluminium backed plates. The plates were visualised under UV fluorescence 
(254 nm) or developed using ninhydrin (0.5% w/v butanol), 2-bromocresol or acidified potassium 
permanganate solution with charring as necessary. Rf values are reported to the nearest 0.01. Mixed 
solvent system compositions are quoted as volumetric ratios. Column chromatography employed 
BDH silica gel (50-70 µm). Reverse phase analytical HPLC was performed on a Grace ODS (4.6 x 150 
mm) column using a Gilson 306 pump with a flow rate of 1 mL min-1. Detection was at 254 nm by a 
Gilson 115 UV detector. Reverse phase semi-preparative HPLC was performed on identical apparatus 
using a Varian ODS 10u (21.2 x 250 mm) column and a 15 mL min-1 flow rate. DataApex Clarity™ 
software was used for integration and analysis. Retention times (in minutes) are quoted to one 
decimal place for the analytical system and are followed in parenthesis by the solvent conditions 
(v/v) used. Silica analytical and semi-preparative HPLC was performed using identical apparatus, 
software and respective flow rates with Silica PhenoSphere™ (4.6 x 250 mm) and Rainin Dynamax™ 
60A (21.4 x 250 mm) columns respectively. Retention times (in minutes) are quoted to one decimal 
place for the analytical system and are followed in parenthesis by the solvent conditions (v/v) used. 
(S)-3-{2-[1-(tert-Butoxycarbonylamino-methyl)-cyclohexyl]-acetoxy}-2-((S)-2-tert-
butoxycarbonylamino-thiopropionylamino)-propionic acid tert-butyl ester (14) 
Gabapentin (85 mg; 0.5 mmol) and di-tert-butyl dicarbonate (130 mg; 0.6 mmol) were suspended in 
1 mL DMF. TEA (0.07 mL; 0.5 mmol) was added and the suspension stirred for four days at room 
temperature. A solution was formed after the first three hours of stirring. The DMF was removed in 
vacuo. HBTU (245 mg; 0.6 mmol) and DIPEA (0.11 mL; 0.6 mmol) were added to the residue, which 
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was then redissolved in 1 mL DMF. The resultant solution was stirred at room temperature for 30 
minutes. 12 (132 mg; 0.4 mmol) in 1 mL DMF was then added and the solution stirred for three days 
at room temperature. The DMF was removed and the residue purified by flash column 
chromatography (4:1 hexane:EtOAc → 1:1 hexane:EtOAc), followed by semi-preparative HPLC (2:1 
hexane:EtOAc) to give title compound as a colourless oil (52 mg; 22%).  HPLC RT: 4.2 (2:1 
hexane:EtOAc). [α]D
31 (CHCl3; c = 3.68): −20.20. υmax (thin film): 3344, 2979, 2931, 2864, 1694, 1514, 
1455, 1393, 1367, 1250, 1163, 1102, 1049, 994, 913, 847, 733. δH (500 MHz, CDCl3): 1.51-1.26 (40H, 
m), 2.31-2.22 (2H, m), 3.07 (1H, dd, J = 14.0 & 6.5), 3.17 (1H, dd, J = 14.0 & 6.5), 4.62-4.40 (3H, m), 
4.91 (1H, s), 5.25 (1H, s), 5.50 (1H, s), 8.99 (1H, s). δC (125 MHz, CDCl3): 21.2, 21.8*, 25.7, 27.7, 27.8*, 
28.2*, 28.2, 28.3*, 28.3, 33.6, 33.8, 37.4, 39.8, 46.9, 56.1, 57.4, 62.7, 79.2, 79.7, 83.1, 154.9, 156.3, 
156.9*, 166.9, 171.6, 206.3, 208.8*. HRMS: Calculated C29H52N3O8S: 624.3289, found: 624.3280.  * 
minor rotamer 
(S)-3-[2-(1-Aminomethyl-cyclohexyl)-acetoxy]-2-((S)-2-amino-thiopropionylamino)-propionic acid 
(2) 
Deprotection of 44 mg of 14 as for compound 1. Yield of 2 as di-TFA salt = 40 mg; 97%. HPLC RT: 4.6 
(10%, Chromolith®). δH (500 MHz, CD3OD): 1.36-1.45 (3H, m), 1.47-1.59 (10H, m), 2.57 (2H, q, J = 
15.5), 3.06 (2H, s), 4.35 (1H, q, J = 6.5), 4.53 (1H, dd, J = 11.5 & 5.5), 4.62 (1H, dd, J = 11.5 & 3.5), 5.30 
(0.1H, t, J = 5.0)*, 5.47 (0.9H, t, J = 5.0). δC (100 MHz, CD3OD): 19.5*, 19.7, 20.9*, 21.1, 22.7*, 25.4*, 
25.6, 25.7*, 32.9*, 33.0, 33.1*, 35.2, 36.5, 47.2, 53.8, 54.5, 63.1*, 63.3, 171.6, 201.5. MS: 
C15H27N3O4S m/z (ES
-) 361.4 [M-H++NH3].  * minor rotamer 
 (S)-2-((S)-2-tert-Butoxycarbonylamino-thiopropionylamino)-succinic acid 1-tert-butyl ester 4-(2,6-
diisopropyl-phenyl) ester (15) 
13 (120 mg; 0.3 mmol) and DCC (83 mg; 0.4 mmol) were stirred in 1 mL DMF for one hour at 0 °C. A 
precipitate was formed during this time. DMAP (7 mg; 0.1 mmol) and 2,6-diisopropylphenol (0.07 
mL; 0.4 mmol) were added. The suspension turned yellow immediately, was warmed to room 
temperature and stirred for 24 hours. The mixture was filtered and the residue washed with DCM. 
The solvent was removed in vacuo and the residue purified by flash column chromatography (DCM 
→ 9:1 DCM:Et2O) to give title compound as a yellow oil (66 mg; 38%). Rf (95:5 DCM:Et2O): 0.58. [α]D
31 
(CHCl3; c = 3.00): +60.20. υmax (thin film): 3323, 2980, 2934, 1728, 1514, 1396, 1370, 1335, 1248, 
1158, 1053, 912, 846, 734. δH (500 MHz, CDCl3): 1.18 (12H, d, J = 5.5), 1.50-1.41 (21H, m), 2.95-2.70 
(2H, m), 3.44-3.35 (1H, m), 3.66-3.55 (1H, m), 4.49 (1H, t, J = 6.5), 5.13 (1H, s), 5.28 (1H, s), 7.15 (2H, 
d, J = 7.5), 7.22 (1H, t, J = 7.5), 8.56 (0.2 H, br s)*, 8.69 (0.8H, d, J = 7.0). δC (100 MHz, CDCl3): 22.1, 
22.8, 24.4, 27.8, 28.2, 34.2, 53.7, 53.9, 83.4, 124.0, 126.8, 140.0, 145.2, 155.1, 168.1, 170.3, 204.9. 
(S)-2-((S)-2-Amino-thiopropionylamino)-succinic acid 4-(2,6-diisopropyl-phenyl) ester (3) 
Deprotection of 66 mg of 15 as for compound 1. Yield of 3 as TFA salt = 23 mg; 39%. HPLC RT: 4.8 
(50%, Chromolith®). δH (500 MHz, CD3OD): 1.17 (6H, s), 1.18 (6H, s),  1.49 (0.8H, dd, J = 7.5 & 6.5)*, 
1.49 (2.2H, d, J = 6.5), 2.85-3.05 (2H, m), 3.22-3.55 (2H, m), 4.27 (0.8H, q, J = 7.0), 4.33 (0.2, q, J = 
7.0)*, 5.53 (1H, br s), 7.15-7.23 (3H, m). δC (100 MHz, CD3OD): 20.9, 23.5, 24.2, 28.3, 28.7, 35.7, 55.2, 
55.7, 125.1, 127.9, 141.8, 146.8, 171.1, 171.9, 202.3. MS: C19H28N2O4S m/z (ES
+) 381.1 [M+H+]. HRMS: 
Calculated C19H29N2O4S: 381.1843, found: 381.1836.  * minor rotamer 
2-(2-Oxo-propyl)-benzoic acid 2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethyl ester (21) 
A suspension of aspirin (345 mg; 1.9 mmol), triphenylphosphine (545 mg; 2.1 mmol) and triethylene 
glycol (0.27 mL; 2.0 mmol) in 0.7 mL THF was sonicated to give a viscous solution. DIAD (0.40 mL; 2.0 
mmol) was then added over 5 minutes to give a yellow solution. This was sonicated for 15 minutes 
at room temperature. The solution was purified by flash column chromatography (4:1 hexane:EtOAc 
→ EtOAc) to give crude product. This was further purified by flash column chromatography (9:1 
DCM:Et2O → EtOAc) to give the atle compound as a colourless oil (294 mg; 49%). Rf (EtOAc): 0.29. 
υmax (thin film): 3489, 2875, 1768, 1723, 1608, 1486, 1453, 1369, 1295, 1258, 1197, 1123, 1082, 916, 
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754. δH (500 MHz, CDCl3): 2.35 (3H, s), 2.63 (1H, br s), 3.58 (2H, t, J = 4.4), 3.66 (4H, br s), 3.68-3.70 
(2H, m), 3.78 (2H, t, J = 4.7), 4.43 (2H, t, J = 4.7), 7.09 (1H, d, J = 8.2), 7.30 (1H, t, J = 7.6), 7.55 (1H, t, J 
= 8.2), 8.05 (1H, d, J = 7.9). δC
 (150 MHz, CDCl3): 20.9, 61.6, 64.0, 69.0, 70.2, 70.6, 72.4, 123.0, 123.7, 
125.9, 131.8, 133.9, 150.6, 164.4, 169.7. MS: C15H20O7 m/z (ES
+) 335.1 [M+Na+]. HRMS: Calculated 
C15H20O7Na: 335.1101, found: 335.1092. 
(S)-2-((S)-2-tert-Butoxycarbonylamino-thiopropionylamino)-succinic acid 4-(2-{2-[2-(2-acetoxy-
benzoyloxy)-ethoxy]-ethoxy}-ethyl) ester 1-tert-butyl ester (22) 
13 (142 mg; 0.4 mmol) and HBTU (294 mg; 0.8 mmol) was dissolved in 2 mL DMF. DIPEA (0.08 mL; 
0.5 mmol) was added to the colourless solution which turned orange almost immediately. The 
solution was stirred at room temperature for one hour at which time it was red/brown in colour. 21 
(287 mg; 0.9 mmol) in 1 mL DMF was then added and the solution stirred for four days at room 
temperature. The DMF was removed under vacuum and the residue purified by flash column 
chromatography (1:1 hexane: EtOAc → EtOAc) to give the title compound as a yellow oil (202 mg; 
80%). Rf  (1:1 hexane:EtOAc): 0.26. [α]D
20 (CHCl3; c = 1.14): +27.94. υmax (thin film): 3337, 2978, 2934, 
1762, 1723, 1607, 1513, 1453, 1393, 1254, 1195, 1083, 1047, 1012, 916, 848. δH
 (500 MHz, CDCl3): 
1.39-1.42 (21H, m), 2.32 (3H, s), 3.00 (1H, dd, J = 17.1 & 3.9), 3.11 (1H, dd, J = 17.1 & 4.0), 3.62-3.67 
(6H, m), 3.75-3.77 (2H, m), 4.12-4.23 (2H, m), 4.40 (2H, t, J = 4.7), 4.42-4.48 (1H, m), 5.17-5.18 
(0.8H), 5.24-5.25 (0.2H, m)*, 5.31-5.33 (0.2H)*, 5.44 (0.8H), 7.07 (1H, dd, J = 7.9 & 1.1), 7.27 (1H, 
ddd, J = 7.9, 7.6 & 1.1), 7.53 (1H, ddd, J = 7.9, 7.6 & 1.6), 8.01 (1H, dd, J = 7.9 & 1.6), 8.66 (0.8H, d, J = 
7.5), 8.73 (0.2H, d, J = 7.5)*. δC
 (150 MHz, CDCl3): 20.8, 21.8, 27.7, 28.1, 34.7, 53.9, 56.8, 63.8 & 69.0, 
68.9, 70.2, 70.4,  79.9, 82.9, 122.9, 123.7, 125.8, 131.7, 133.8, 150.5, 154.7, 164.2, 168.2, 169.5, 
170.3, 170.8*, 205.0. MS: C31H46N2O12S m/z (ES
+) 688.6 [M+NH4
+]. HRMS: Calculated C31H50N3O12S: 
688.3110, found: 688.3125.  * minor rotamer 
(S)-2-((S)-2-Amino-thiopropionylamino)-succinic acid 4-(2-{2-[2-(2-acetoxy-benzoyloxy)-ethoxy]-
ethoxy}-ethyl) ester (4) 
Deprotection of 65 mg of 22 as for compound 1. Yield of 4 as TFA salt = 52 mg; 85%. Rf  (1:1:1:1 
EtOAc:BuOH:H2O:CH3CO2H): 0.42. [α]D
24 (MeOH; c = 0.82): +29.44. δH
 (500 MHz, D2O): 1.40 (0.4H, d, J 
= 6.9)*, 1.46 (2.6H, d, J = 6.9), 2.27 (3H, s), 2.87-3.01 (2H, m), 3.52-3.68 (6H, m), 3.72-3.78 (1.7H, m), 
3.79-3.82 (0.3H, m)*, 4.00-4.07 (0.3H, m)*, 4.08-4.15 (1.7H, m), 4.33 (1H, q, J = 6.9), 4.31-4.38 (1.7H, 
m),  4.37-4.33 (0.3H, m)*, 5.15-5.28 (1H, m), 7.12 (1H, dd, J = 7.9 & 1.3), 7.34 (1H, ddd, J = 7.9, 7.6 & 
1.3), 7.60 (1H, ddd, J = 7.9, 7.6 & 1.6), 7.94 (1H, dd, J = 7.9 & 1.6). δC
 (150 MHz, D2O): 17.7*, 18.2, 
18.6, 38.3, 50.9, 51.1, 62.1, 65.9, 67.2, 67.9, 69.3, 120.1, 121.7*, 124.5, 129.4, 131.4, 137.4, 147.2, 
160.5, 163.8, 169.9, 170.9, 198.7. MS: C22H30N2O10S m/z (ES
+) 515.4 [M+H+]. HRMS: Calculated 
C22H31N2O10S: 515.1694, found: 515.1697.  * minor rotamer. 
(S)-2-((S)-2-tert-Butoxycarbonylamino-thiopropionylamino)-succinic acid 4-[2-(2-amino-6-oxo-1,6-
dihydro-purin-9-ylmethoxy)-ethyl] ester 1-tert-butyl ester (16) 
13 (124 mg; 0.3 mmol) and DCC (68 mg; 0.3 mmol) were dissolved in 0.3 mL DMF and cooled to 0 °C. 
The reaction was stirred at this temperature for one hour during which time a white precipitate was 
formed. A solution of acyclovir (50 mg; 0.2 mmol) and DMAP (10 mg; 0.1 mmol) in 1.5 mL DMF was 
then added. The suspension was warmed to room temperature and stirred for 24 hours during 
which time the suspension changed from orange-brown to a brown-purple colour. The suspension 
was filtered and the filtrate washed with the minimum of DCM. The liquor was concentrated and the 
residue purified by flash column chromatography (95:5 CHCl3:MeOH → 9:1 CHCl3:MeOH) to give the 
title compound as a brown solid (123 mg; 96%). Rf (CHCl3:CH3OH, 9:1): 0.46. [α]D
25 (CHCl3; c = 0.98): 
+7.20. υmax (thin film): 3311, 3107, 2982, 2941, 1696, 1602, 1534, 1484, 1371, 1254, 1157, 1102, 
1057, 845, 758. δH (CD3OD, 300 MHz): 1.41 (3H, d, J = 6.8), 1.49-1.63  (18H, m), 2.88-3.03 (2H, m), 
3.71-3.80 (2H, m), 4.14-4.22 (2H, m), 4.41-4.48 (1H, m), 5.23-5.28 (1H, m), 5.49 (2H, s), 7.88 (1H, s). 
δC (CD3OD, 75 MHz): 22.2, 28.5, 29.1, 36.1, 56.2, 57.5, 65.2,65.2, 68.7, 68.7, 74.1, 79.9, 84.2, 118.7, 
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140.2, 153.2, 156.0, 156.9, 159.6, 170.3, 172.0, 206.5. MS: C24H38N7O8S m/z (ES
+) 584.1 [M+Na+]. 
HRMS: Calculated C24H38N7O8SNa: 584.2497, found: 584.2503.  
(S)-2-((S)-2-Amino-thiopropionylamino)-succinic acid 4-[2-(2-amino-6-oxo-1,6-dihydro-purin-9-
ylmethoxy)-ethyl] ester (5) 
A mixture of 16 (51 mg; 0.1 mmol) and phenol (179 mg; 1.9 mmol) was heated to 45 °C at which 
point the now liquid phenol had dissolved. Trifluoroacetic acid (0.03 mL; 0.4 mmol) was then added 
and the solution stirred at 45 °C for one hour. The solution was diluted with 2 mL EtOAc and washed 
three times with 3 mL water. The EtOAc was removed in vacuo and the residue sequentially taken up 
in DMF and water, both of which were removed under vacuum. The resultant residue, which was 
free from phenol contamination, was redissolved in 5 mL water and lyophilised to give di-TFA salt of 
5 as an off white solid (28 mg; 44%). δH (D2O, 300 MHz): 1.37 (0.4H, d, J = 7.0)*, 1.50 (2.6H, d, J = 
7.0), 2.80-2.91 (2H, m), 3.77-3.84 (2H, m), 4.13-4.20 (2H, m), 4.26 (1H, q, J = 6.9), 5.03-5.11 (1H, m), 
5.47 (2H, s), 8.09 (0.9H, s), 8.50 (0.1H, s)*. δC (D2O, 75 MHz): 19.8, 34.7, 53.9, 54.2, 54.4, 54.8*, 64.2, 
67.8, 74.3, 118.4, 138.5, 150.6, 162.9, 171.8, 172.4, 201.2. MS: C15H21N7O6S m/z (ES
+) 428.0 [M+H+]. 
HRMS: Calculated C15H22N7O6S: 428.1347, found: 428.1336.  * minor rotamer. 
(S)-4-((S)-3-(4-(2-amino-2-oxoethyl)phenoxy)-1-(tert-butoxycarbonyl)propan-2-yl) 1-tert-butyl 2-
((S)-2-(tert-butoxycarbonyl)propanethioamido)succinate (17) 
S(-)-Atenolol (100 mg, 0.37 mmol) was dissolved in water (10 ml) containing (59 mg, 0.56 mmol) of 
sodium carbonate and the mixture was cooled to 0 0C with stirring. Then, the solution of di-tert. 
butyl dicarbonate (125 mg, 0.57 mmol) in 10 ml of 1,4-dioxane was slowly added at the same 
temperature. The mixture was stirred overnight at room temperature, evaporated in vacuo to get 
white solid, diluted with 20 ml of water, and extracted with three portions of ethyl acetate. The ethyl 
acetate solution was washed with brine, dried (MgSO4) and evaporated in vacuo to afford white 
solid (131 mg). A solution of this in 10 mL MeCN was slowly added over 20 minutes to a solution of 
13 (150 mg, 0.39 mmol) in MeCN (15 ml) containing (117 mg, 0.71 mmol) of 1,1’-carbonyl 
diimidazole and (14 mg, 0.2 mmol) of imidazole. The mixture was stirred for 3 days at room 
temperature under the inert atmosphere. The precipitated solid was filtered off and the filtrate was 
evaporated in vacuo to get thick brown gel, which can further diluted with 30 ml of EtOAc, and 
washed with 2M HCl (2 x 10 ml), saturated aqueous NaHCO3 (3 x 10 ml), water (2 x 10ml) and finally 
with the brine (20 ml), dried (MgSO4) and evaporated in vacuo to afford white crude solid. The 
residue was purified by flash column chromatography (3:7 petrol:EtOAc → EtOAc) to give desired 
product as a white solid (130 mg; 36%). M.p. 64-67 °C. Rf 0.40 [Petrol-EtOAc 2:8]. [α]D
25 (CHCl3; c = 
0.028): 34.97. υmax (neat)/cm
-1  3675, 3338, 2973, 2901, 1690, 1667, 1614, 1511, 1453, 1406, 1393, 
1366, 1242, 1155, 1050, 900, 846, 775, 731, 435. δH (300 MHz, CDCl3):  1.10 (6H, s), 1.32-1.42 (30H,  
m),  2.91 (1H, br s), 3.35 (1H, br s),  3.40-3.45 (3H, m), 3.92-4.12 (3H, m), 4.33-4.45 (1H, m), 5.10-5.22 
(1H,  m), 5.22-5.30 (1H, m), 5.30-5.42 (1H, m), 5.70-5.80 (1H, m), 6.82 (2H, d, J = 8.7), 7.15 (2H, d, J = 
8.5). δC (75 MHz, CDCl3): 17.5, 21.0, 22.1, 22.6, 23.8, 27.8, 28.2, 28.4, 29.3, 29.6, 31.9, 34.9, 42.3, 
43.2, 53.9, 56.0, 57.0, 67.4, 80.1, 83.1, 115.1, 127.5, 130.6, 154.8, 157.6, 168.2, 174.1, 205.4. HRMS: 
Calculated C35H56N4O10S 725.3790, found 725.3795. MS C35H55N4O10S m/z (ES
+) 725.37 [M+H+]. 
(S)-4-((S)-3-(4-(2-amino-2-oxoethyl)phenoxy)-1-(isopropylamino)propan-2-yloxy)-2-((S)-2-
aminopropanethioamido)-4-oxobutanoic acid (8) 
17 (100 mg, 0.138 mmol) was dissolved in 3 mL 97% formic acid. The solution was refluxed at 100 0C 
for three hours, followed by room temperature for overnight. The excess formic acid was then 
removed under high vacuum and the residue taken up in 2 mL distilled water. The fine suspension 
was filtered through a pipette plugged with glass wool and lyophilised to give the formate salt of 8 as 
a brown solid (53 mg; 76%). M.p. 118-121 °C. [α]D
29 (MeOH; c = 0.028): -35.71. υmax (neat)/cm
-1 3648, 
3195, 2972, 2116, 1869, 1830, 1738, 1667, 1583, 1510, 1456, 1380, 1346, 1298, 1240, 1176, 1082, 
1066, 1046, 920, 879, 798, 763, 668, 567, 518. δH (300 MHz, D2O):  1.1 (6H, d, J = 6.4), 1.42 (3H, d, J = 
6.8),  2.73-2.92 (2H, m), 3.22-3.41 (5H, m),  4.10-4.25 (3H, m), 4.91 (1H, t, J = 6.4), 5.31-5.42 (1H, m), 
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6.83 (2H, d, J = 8.7), 7.15 (2H, d, J = 8.7), 8.23 (2H, s). δC (75 MHz, D2O): 17.7, 18.1, 19.2, 35.4, 40.6, 
44.7, 51.4, 53.7, 56.7, 66.9, 68.9, 114.9, 128.2, 130.5, 156.6, 167.8, 174.7, 177.7, 199.3. MS: 
C21H32N4O6S m/z (ES
+) 468.2 [M+]. HRMS: Calculated for C21H32N4O6S 468.2043, found 468.1999 
(4S,5R,6R)-5-acetamido-6-((1R,2R)-3-((S)-4-tert-butoxy-3-((S)-2-(tert-
butoxycarbonyl)propanethioamido)-4-oxobutanoyloxy)-1,2-dihydroxypropyl)-4-guanidino-5,6-
dihydro-4H-pyran-2-carboxylic acid (18) 
A mixture of 13 (100 mg, 0.26 mmol), HATU (117mg, 0.30mmol) and DIPEA (0.15ml, 0.8mmol) in 
anhydrous DMF (10 ml) was stirred under nitrogen at 0 0C for 30 min. then a solution of Relenza (97 
mg, 0.29 mmol) in the mixture of dry DMF:DMSO(10 ml, 8:2) was added and stirring was continued  
for another 3 days at room temperature. The reaction mixture were filtered off and the filtrate, plus 
a DMF washing, was evaporated in vacuo to get crude oil, which was further purified by 
chromatography, eluting with neat EtOAC to 1:1 (MeOH : EtOAC) to give desired product as an off 
white solid (20 mg, 11%). M.p. 282-284 °C. Rf 0.40 [MeOH-EtOAc 3:7]. [α]D
25 (CH3OH; c = 0.028): 
35.71. υmax (neat)/cm
-1  3668, 3244, 2988, 2972, 2901, 1704, 1689, 1568, 1453,1405, 1322, 1250, 
1155, 1049, 894, 609, 548. δH (300 MHz, CD3OD):  1.40 (22H, s),  2.00 (5H, s), 2.65 (1H, s), 3.00-3.10 
(2H, m), 3.40 (1H, br s, -OH), 3.60-3.75 (1H, m, 3.75-3.90 (1H, m), 4.00-4.25 (4H, m), 4.30-4.50 (3H, 
m), 5.20-5.25 (1H, m), 5.50 (1H, s). δC (75 MHz, D2O): 21.8, 26.9, 27.4, 47.6, 48.0, 51.0, 62.9, 67.9, 
69.6, 75.2, 82.0, 103.8, 130.0, 149.0, 152.0, 156.8, 170.0, 174.2, 184.0. MS: C28H46N6O12S m/z (ES
+) 
691.3 [M+H+]. HRMS Calculated for C28H47N6O12S 691.2967, found 691.2973. 
(4S,5R,6R)-5-acetamido-6-((1R,2R)-3-((S)-3-((S)-2-aminopropanethioamido)-3-
carboxypropanoyloxy)-1,2-dihydroxypropyl)-4-guanidino-5,6-dihydro-4H-pyran-2-carboxylic acid 
(9) 
Deprotection of 100 mg of 18 as for compound 8. Yield of 9 as formate salt = 54 mg; 70%. M.p. 210-
212°C. [α]D
29 (H2O; c = 0.057): 17.54. υmax (neat)/cm
-1 3325, 3178, 2924, 2111, 1717, 1680, 1589, 
1374, 1324, 1282, 1146, 1041, 945, 768, 665. δH (300 MHz, D2O):  1.42 (3H, s), 1.92 (3H, s), 2.73-2.90 
(3H, m), 3.45-3.55 (2H, m), 3.73-3.82 (2H, m), 4.02-4.11 (1H, m), 4.15-4.30 (3H, m), 4.82-4.91 (1H, 
m), 5.53 (1H, s), 8.22 (1H, s). δC (75 MHz, D2O): 19.2, 21.8, 37.0, 47.5, 50.9, 53.0, 57.2, 62.0, 67.9, 
69.6, 75.2, 104.1, 136.0, 150.0, 156.8, 174.2, 180.0, 199.6. MS: C19H30N6O10S m/z (ES
+) 534.2 [M+].  
HRMS: Calculated for C19H30N6O10S 534.1744, found 534.1698. 
(R)-((S)-3-tert-butoxy-2-((S)-2-(tert-butoxycarbonyl)propanethioamido)-3-oxopropyl) 4-(tert-
butoxycarbonyl)-3-(4-chlorophenyl)butanoate (19) 
A mixture of Boc-baclofen (210 mg, 0.66 mmol), DCC (140.5 mg, 0.68 mmol) and DMAP (5 mg, 0.05 
mmol) in anhydrous DCM (20 ml) was stirred at room temperature for 15 min. under the inert 
atmosphere. Then, the solution of 12 (163 mg, 0.468 mmol) in 10 ml of DCM was slowly added at the 
same temperature. The mixture was stirred for 5 h at room temperature under the inert 
atmosphere. The precipitated solid was filtered off and the filtrate was evaporated in vacuo to get 
viscous liquid, which can further diluted with 30 ml of EtOAc, and washed with 2M HCl (2 x 10 ml), 
saturated aqueous NaHCO3 (3 x 10 ml), water (2 x 10 ml) and finally with the brine (20 ml), dried 
(MgSO4) and evaporated in vacuo to afford white crude solid. The residue was purified by flash 
column chromatography (9:1 petrol:EtOAc → 7:3 petrol:EtOAc) to give desired product as a white 
solid (280 mg; 65%). M.p. 65-68 °C, Rf 0.50 [Petrol-EtOAc 8:2]. [α]D
28 (CHCl3; c = 0.028): 71.43. υmax 
(neat)/cm-1: 3325, 2976, 2928, 2851, 1991, 1693, 1626, 1574, 1510, 1493, 1449, 1411,  1393, 1366, 
1310, 1244, 1190, 1108, 1088, 1048, 1014, 967, 843, 827, 641, 534. δH (300 MHz, CDCl3): 1.42 (30H,  
s),  2.53 (1H, dd, J = 7.5 & 6.4), 2.62 (1H, dd, J = 7.5 & 6.4)  3.11-3.33 (2H, m), 3.33-3.42 (1H, m), 4.35 
(1H, dd, J = 11.5 & 2.8), 4.41-4.53 (2H,  m), 4.55 (1H, dd, J = 11.5 & 2.4), 5.15-5.25 (1H, br m), 5.62 
(1H, br s), 7.15 (2H, d, J = 8.5), 7.25 (2H, d, J = 8.3), 8.83 (1H, br s). δC (75 MHz, CDCl3): 21.7, 27.8, 
28.3, 28.38, 33.8, 37.6, 41.3, 57.1, 57.3, 62.9, 79.4, 82.7, 83.4, 128.9, 132.9, 139.7, 155.9, 167.2, 
170.9, 206.2. MS: C30H46ClN3O8S m/z (ES
+) 644.3 [M+H+].  HRMS: Calculated for C30H47ClN3O8S 
644.2195, found 644.2759. 
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(S)-3-((R)-4-amino-3-(4-chlorophenyl)butanoyloxy)-2-((S)-2- aminopropanethioamido)propanoic 
acid (10) 
Deprotection of 100 mg of 19 as for compound 8. Yield of 10 as formate salt = 54 mg; 80%. M.p. 112-
115 °C. [α]D
28 (H2O; c = 0.057): -17.54. υmax (neat)/cm
-1: 3195, 2979, 2112, 1869, 1730, 1704, 1688, 
1582, 1511, 1490, 1456, 1379, 1241, 1164, 1110, 1089, 1050, 1013, 897, 823, 764, 668, 527; δH (300 
MHz, D2O): 1.42 (3H,  s), 2.45-2.62 (1H, m), 2.62-2.75 (1H, m), 3.05-3.15 (1H, m), 3.15-3.35 (2H, m), 
4.25-4.35 (1H, m), 4.35-4.45 (1H,  m), 4.82-5.01 (2H, m), 7.22 (2H, d, J = 8.7), 7.31 (2H, d, J = 8.3), 
8.35 (1H, s). δC (75 MHz, D2O): 19.2, 37.8, 39.1, 40.3, 53.7, 59.7, 63.9, 132.9, 133.3, 136.7, 137.6, 
172.6, 173.0, 199.6. MS: C16H22ClN3O4S m/z (ES
+) 388.1 [M+H+].  HRMS: Calculated for C16H23ClN3O4S 
388.1098, found 388.1102.  
(E)-((S)-3-tert-butoxy-2-((S)-2-(tert-butoxycarbonyl)propanethioamido)-3-oxopropyl) 6-(4-hydroxy-
6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (20) 
A mixture of 12 (94 mg, 0.27 mmol), mycophenolic acid (100 mg, 0.31 mmol) and N-
methylmorpholine (137 mg, 1.24 mmol) in anhydrous MeCN (10 ml) was stirred with 3 Å molecular 
sieves under nitrogen at 20 °C for 2 h, then a solution of HATU (130 mg, 0.34 mmol) in MeCN (5 ml) 
was added and stirring was continued  for another 2 days. The reaction was monitored by TLC (7:3 
Petrol : EtOAC). The reaction mixture were filtered off and the filtrate, plus an MeCN washing, was 
evaporated in vacuo to get crude solid, which can further diluted with 30 ml of EtOAc, and washed 
with 2M HCl (2x10ml), saturated aqueous NaHCO3 (3x10 ml), Water (2x10 ml) and finally with brine 
(20 ml), dried (MgSO4) and evaporated in vacuo to afford white crude solid, which was further 
purified by chromatography, eluting with 9:1 (Petrol : EtOAC) to 7.5:1 (Petrol : EtOAC) to give desired 
product as a white solid (40 mg, 20%). M.p. 69-72 °C. Rf 0.50 [Petrol-EtOAc 1:1]. [α]D
20 (CHCl3; c = 
0.028): 35.71. υmax (neat)/cm
-1: 3326, 2976, 2930, 2115, 1991, 1868, 1738, 1732, 1716, 1699, 1622, 
1564, 1506, 1454, 1411, 1393, 1367, 1329, 1245, 1179, 1130, 1049, 1038, 994, 969, 844, 792, 545. δH 
(300 MHz, CDCl3): 1.42 (21H,  s),  1.73 (3H, s), 2.14 (3H, s), 2.22 (2H, t, J = 6.8), 2.25-2.35 (2H, m), 3.32 
(2H, d, J = 6.8), 3.74 (3H, s), 4.35-4.53 (3H, m), 5.12-5.23 (4H, m), 7.62 (1H, s), 8.53 (1H, m). δC (75 
MHz, CDCl3): 11.6, 16.1, 21.7, 22.5, 27.8, 28.2, 32.6, 34.3, 57.3, 61.0, 62.8, 70.1, 80.3, 83.5, 106.4, 
116.7, 122.02, 122.8, 133.8, 144.1, 153.5, 163.6, 167.3, 172.8, 172.9, 205.6. MS: C32H46N2O10S m/z 
(ES+) 651.3 [M+H+].  HRMS: Calculated for C32H47N2O10S 651.2951, found 651.2928. 
 
(S)-2-((S)-2-aminopropanethioamido)-3-((E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-
dihydroisobenzofuran-5-yl)-4-methylhex-4-enoyloxy)propanoic acid (11) 
Deprotection of 100 mg of 20 as for compound 8. Yield of 11 as formate salt = 50 mg; 65%. M.p. 140-
143 0C. [α]D
29 (H2O; c = 0.057): -35.09. υmax (neat)/cm
-1: 3746, 3219, 2974, 2934, 2247, 2119, 1830, 
1737, 1731, 1688, 1668, 161, 1606, 1558, 1539, 1532, 1516, 1452, 1409, 1380, 1325, 1303, 1251, 
1187, 1135, 1107, 1075, 1033, 966, 938, 788, 642, 589, 542. δH (300 MHz, D2O): 1.22 (3H,  d, J = 3.8),  
1.43 (3H, s), 1.62-1.75 (3H, m), 1.91 (3H, s), 2.31-2.42 (2H, m), 2.52-2.63 (2H, m), 2.73-2.81 (1H, m), 
3.02-3.11 (1H, m), 3.72 (3H, s), 4.21-4.43 (4H, m), 5.02-5.11 (3H, m), 8.01 (1H, s). δC (75 MHz, 
CD3OD): 11.4, 16.5, 20.5, 31.8, 33.2, 55.0, 62.9, 64.0, 70.8, 83.1, 120.0, 123.7, 124.2, 135.0, 162.5, 
166.1, 170.8, 173.0, 201.2.  MS: C23H30N2O8S m/z (ES
+) 494.2 [M+].  HRMS: Calculated for C23H30N2O8S 
494.1723, found 494.1676. 
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• The intestinal oligopeptide transporter PepT1 is a key target for oral drug delivery 
• Non-orally bioavailable compounds conjugated to thioamides became PepT1 substrates 
• Transport of these prodrugs was shown in biological systems, including in vivo 
• The wide range of prodrugs synthesised demonstrates the versatility of the approach 
• Thioamide conjugation is a general means of improving poor drug oral permeability 
